DnB Asset Management
FOLD

DnB Asset Management’s Amicus Therapeutics FOLD Stock Holding History

DnB Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
+14,662
New +$210K ﹤0.01% 1137
2025
Q4 		– Sell
-46,161
Closed -$364K – 746
2025
Q3 		$364K Buy
46,161
+6,920
+18% +$49.2K ﹤0.01% 685
2025
Q2 		$225K Buy
39,241
+3,722
+10% +$24K ﹤0.01% 690
2025
Q1 		$290K Buy
35,519
+3,077
+9% +$28.5K ﹤0.01% 690
2024
Q4 		$306K Sell
32,442
-231
-0.7% -$2.4K ﹤0.01% 686
2024
Q3 		$349K Buy
32,673
+490
+2% +$5.34K ﹤0.01% 673
2024
Q2 		$319K Buy
32,183
+5,165
+19% +$53K ﹤0.01% 673
2024
Q1 		$318K Buy
27,018
+2,182
+9% +$27.9K ﹤0.01% 674
2023
Q4 		$352K Buy
24,836
+550
+2% +$6.25K ﹤0.01% 639
2023
Q3 		$295K Sell
24,286
-5,903
-20% -$76.1K ﹤0.01% 652
2023
Q2 		$379K Buy
30,189
+8,818
+41% +$105K ﹤0.01% 645
2023
Q1 		$237K Buy
21,371
+3,217
+18% +$39.7K ﹤0.01% 644
2022
Q4 		$222K Sell
18,154
-2,924
-14% -$32.9K ﹤0.01% 634
2022
Q3 		$220K Sell
21,078
-4,617
-18% -$51.4K ﹤0.01% 641
2022
Q2 		$276K Buy
+25,695
New +$212K ﹤0.01% 647
2022
Q1 		– Sell
-22,837
Closed -$264K – 653
2021
Q4 		$264K Sell
22,837
-151,441
-87% -$1.69M ﹤0.01% 659
2021
Q3 		$1.67M Buy
174,278
+149,898
+615% +$1.53M 0.01% 565
2021
Q2 		$235K Buy
+24,380
New +$238K ﹤0.01% 629
2021
Q1 		– Sell
-15,728
Closed -$363K – 640
2020
Q4 		$363K Sell
15,728
-12,822
-45% -$262K ﹤0.01% 614
2020
Q3 		$403K Sell
28,550
-28,218
-50% -$411K ﹤0.01% 590
2020
Q2 		$856K Buy
+56,768
New +$692K 0.01% 529

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

DnB Asset Management's FOLD Position: Q1 2026 in Review

DnB Asset Management opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 14,662 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1137 among its holdings. This is a return to the name: DnB Asset Management previously reported a position in FOLD as recently as Q3 2025.

DnB Asset Management first reported a position in FOLD in Q2 2020 and has held it in 21 quarters since. The position peaked at $1.67M in Q3 2021. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • DnB Asset Management held 14,662 shares of Amicus Therapeutics worth $212K as of Q1 2026.
  • Amicus Therapeutics was a new DnB Asset Management position in Q1 2026.
  • Amicus Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q1 2026, its #1137 holding.
  • DnB Asset Management first reported a position in Amicus Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • DnB Asset Management's Amicus Therapeutics position peaked at $1.67M in Q3 2021.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.